Archive

HIGHLIGHTS

 
LSP leads € 15M series A round of Cardiovascular start-up Cardior Pharmaceuticals
Munich, Germany — May 11, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Cardior Pharmaceuticals, a private German company develo[...]
 
LSP Portfolio Company Luxendo acquired by Bruker
Successful exit after 1,5 years validates LSPs investment rationale   Munich, Germany ─ May 8, 2017 ─ LSP today announced that it has sold its portfolio company Luxendo, a spin-off of the European Molecul[...]
 
LSP extends its portfolio in immuno-oncology and invests in the € 20 million Series A round of Imcheck Therapeutics
Amsterdam, the Netherlands — May 3, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Imcheck Therapeutics, a private French company[...]
 
LSP’s portfolio company Neuravi acquired by Codman Neuro
Amsterdam, the Netherlands, April 10, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces the acquisition of its portfolio company Neuravi Limited by Codman Neuro, part of the [...]
 
LSP’s portfolio company argenx raises approximately $100 million with NASDAQ IPO
Amsterdam, The Netherlands – 19 May 2017 – It is with great pleasure that LSP – the specialist European healthcare investment firm – announces that its portfolio company argenx (Euronext Brussels: ARGX) was su[...]
 
Marco Groot over LSP in het FD
Lees de gehele column: Een absoluut beter resultaat
 
LSP announces $280 million final closing of life sciences venture fund
Amsterdam, 2nd June 2016 - LSP (Life Sciences Partners), the European life sciences investment group, today announced the final closing of its new life sciences fund, LSP 5. The fund surpassed its $170 million target [...]
 
LSP and Bristol-Myers Squibb enter into strategic collaboration for life sciences innovation in Europe
First investment by Bristol-Myers Squibb in a European healthcare fund      Munich and New York, 24 November, 2015—LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced to[...]
 
LSP Venture Partner Hans Clevers gets prestigious Körber Award for his ground breaking research into stem cells and organoids, and appears in Germ...
To see the video click here    
 
Wireless brain-spine connection to overcome paralysis
Prof Grégoire Courtine and Dr. Jocelyne Bloch, both founders of LSP’s portfolio company G-Therapeutics, have published in Nature that a wireless brain implant – that stimulates electrodes in the leg by recreating[...]
 
LSP’s portfolio company Merus announces global strategic collaboration with Incyte
LSP’s portfolio company Merus announces global strategic collaboration with Incyte to discover and develop bispecific antibodies   Upfront payment of $120 million plus equity investment of $80 million (at[...]

2017


argenx receives second preclinical milestone payment in collaboration with LEO Pharma
Breda, the Netherlands / Ghent, Belgium, June 20, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Zealand Pharma announces positive results from the Phase 2 trial of glepaglutide
Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome   Glepaglutide* is a novel long-acting GLP-2 analogue  Reduction in fecal wet weight output of 30% and 23% i [...]
argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas at the International Conference of Maligna...
Breda, the Netherlands / Ghent, Belgium, June 14, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
LSP’s portfolio company Probiodrug reports positive results in Alzheimer Disease Patients
Munich/Amsterdam – 13 June 2017 – LSP proudly announces that its portfolio company Probiodrug AG released encouraging results from its clinical trial in early Alzheimer’s disease patients. Treatment with Pro [...]
Ventaleon GmbH Initiates Challenge Trial with Inhaled Flu Treatment Candidate
Human challenge study to assess safety, tolerability and efficacy of inhaled LASAG Topline results expected end of 2017 Gemuenden, Germany, 31 May, 2017. Ventaleon GmbH, a biotechnology company focu [...]
Zealand Pharma announces positive Phase 2a results with microdoses of dasiglucagon support use in a dual-hormone artificial pancreas system
Dasiglucagon is a potential first-in-class glucagon analogue for pump use in the management of type 1 diabetes  Data from this first Phase 2a trials indicate that dasiglucagon increases blood sugar levels a [...]


2017
2016
2015
2014
2013
2012
back to news overview

Archive

HIGHLIGHTS

 
LSP leads € 15M series A round of Cardiovascular start-up Cardior Pharmaceuticals
Munich, Germany — May 11, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Cardior Pharmaceuticals, a private German company develo[...]
 
LSP Portfolio Company Luxendo acquired by Bruker
Successful exit after 1,5 years validates LSPs investment rationale   Munich, Germany ─ May 8, 2017 ─ LSP today announced that it has sold its portfolio company Luxendo, a spin-off of the European Molecul[...]
 
LSP extends its portfolio in immuno-oncology and invests in the € 20 million Series A round of Imcheck Therapeutics
Amsterdam, the Netherlands — May 3, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Imcheck Therapeutics, a private French company[...]
 
LSP’s portfolio company Neuravi acquired by Codman Neuro
Amsterdam, the Netherlands, April 10, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces the acquisition of its portfolio company Neuravi Limited by Codman Neuro, part of the [...]
 
LSP’s portfolio company argenx raises approximately $100 million with NASDAQ IPO
Amsterdam, The Netherlands – 19 May 2017 – It is with great pleasure that LSP – the specialist European healthcare investment firm – announces that its portfolio company argenx (Euronext Brussels: ARGX) was su[...]
 
Marco Groot over LSP in het FD
Lees de gehele column: Een absoluut beter resultaat
 
LSP announces $280 million final closing of life sciences venture fund
Amsterdam, 2nd June 2016 - LSP (Life Sciences Partners), the European life sciences investment group, today announced the final closing of its new life sciences fund, LSP 5. The fund surpassed its $170 million target [...]
 
LSP and Bristol-Myers Squibb enter into strategic collaboration for life sciences innovation in Europe
First investment by Bristol-Myers Squibb in a European healthcare fund      Munich and New York, 24 November, 2015—LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced to[...]
 
LSP Venture Partner Hans Clevers gets prestigious “Körber Award” for his ground breaking research into stem cells and organoids, and appears in Germ...
To see the video click here    
 
Wireless brain-spine connection to overcome paralysis
Prof Grégoire Courtine and Dr. Jocelyne Bloch, both founders of LSP’s portfolio company G-Therapeutics, have published in Nature that a wireless brain implant – that stimulates electrodes in the leg by recreating[...]
 
LSP’s portfolio company Merus announces global strategic collaboration with Incyte
LSP’s portfolio company Merus announces global strategic collaboration with Incyte to discover and develop bispecific antibodies   Upfront payment of $120 million plus equity investment of $80 million (at[...]

$smarty.now|date_format:"%Y"


argenx receives second preclinical milestone payment in collaboration with LEO Pharma
Breda, the Netherlands / Ghent, Belgium, June 20, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Zealand Pharma announces positive results from the Phase 2 trial of glepaglutide
Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome   Glepaglutide* is a novel long-acting GLP-2 analogue  Reduction in fecal wet weight output of 30% and 23% i [...]
argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas at the International Conference of Malig...
Breda, the Netherlands / Ghent, Belgium, June 14, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
LSP’s portfolio company Probiodrug reports positive results in Alzheimer Disease Patients
Munich/Amsterdam – 13 June 2017 – LSP proudly announces that its portfolio company Probiodrug AG released encouraging results from its clinical trial in early Alzheimer’s disease patients. Treatment with Pro [...]
Ventaleon GmbH Initiates Challenge Trial with Inhaled Flu Treatment Candidate
Human challenge study to assess safety, tolerability and efficacy of inhaled LASAG Topline results expected end of 2017 Gemuenden, Germany, 31 May, 2017. Ventaleon GmbH, a biotechnology company focu [...]
Zealand Pharma announces positive Phase 2a results with microdoses of dasiglucagon support use in a dual-hormone artificial pancreas system
Dasiglucagon is a potential first-in-class glucagon analogue for pump use in the management of type 1 diabetes  Data from this first Phase 2a trials indicate that dasiglucagon increases blood sugar levels a [...]


2017
2016
2015
2014
2013
2012
back to news overview